Edition:
Deutschland

Abbvie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

96.58USD
10 Jul 2020
Change (% chg)

$-1.36 (-1.39%)
Prev Close
$97.94
Open
$98.06
Day's High
$98.29
Day's Low
$96.51
Volume
205,412
Avg. Vol
3,003,157
52-wk High
$100.68
52-wk Low
$62.55

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Buy/Sell

Sell Hold Buy
1.89 Mean rating from 18 analysts

Overall

Beta: 1.53
Market Cap(Mil.): $144,249.59
Shares Outstanding(Mil.): 1,594.09
Dividend: 0.64
Yield (%): 2.83
Photo

U.S. signs $450 million contract with Regeneron for COVID-19 therapy

The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday.

UPDATE 2-U.S. signs $450 mln contract with Regeneron for COVID-19 therapy

July 7 The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday.

Regeneron starts COVID-19 antibody cocktail late-stage trials, shares rise

Regeneron Pharmaceuticals Inc said on Monday it has started late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.

UPDATE 3-Regeneron starts COVID-19 antibody cocktail late-stage trials, shares rise

July 6 Regeneron Pharmaceuticals Inc said on Monday it has started late-stage clinical trials to assess the effectiveness of its antibody cocktail in preventing and treating COVID-19.

Canada federal court dismisses drugmakers' plea challenging drug price rules

June 29 The federal court of Canada on Monday dismissed a plea by drugmakers challenging the Canadian government's new regulations aimed at lowering prices of patented drugs that could potentially lead them to lose billions over a decade.

UPDATE 1-HIV treatment found to have no benefit for hospitalised COVID-19 patients in trial

LONDON, June 29 A combination of antiviral drugs used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large-scale randomised trial, British scientists said on Monday.

Antiviral HIV drug found to have no benefit for hospitalised COVID-19 patients in UK trial

LONDON, June 29 British scientists on Monday said that an antiviral drug commonly used to treat HIV had no beneficial effect in patients hospitalised with COVID-19 in a large scale randomised trial.

UPDATE 1-Molecular Partners hopes for COVID-19 rebound after eye drug failure

ZURICH, June 26 Molecular Partners aims to test its COVID-19 drug candidate on people later this year, Chief Executive Patrick Amstutz said on Friday, as the Swiss company hopes that project will help it recover from the failure of its eye drug abicipar.

Molecular Partners hopes for COVID-19 rebound after eye drug failure

ZURICH, June 26 Molecular Partners aims to treat patients with its COVID-19 drug candidate this year, Chief Executive Patrick Amstutz said on Friday, as the Swiss company hopes it will help it recover from the failure of its eye drug abicipar.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.06%
Rohstoffe -0.14%
Industrie -0.53%
Konjunktur abhängige Waren & Dienstleistungen +0.20%
Konjunktur unabhängige Waren & Dienstleistungen +0.35%
Finanzindustrie -0.76%
Pharma -0.98%
Technologie +0.15%
Telekommunikation +0.44%